CF PharmTech (HKSE:02652) EBIT: HK$-12.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02652 CF PharmTech Inc HKSE:02652
15 GF Score
Price HK$17.35
! 5 Warning Signs
View Full Analysis

What is CF PharmTech EBIT?

CF PharmTech HKSE:02652 +0.81% 15 EBIT is HK$-12.0 Mil as of Dec. 2025. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review.

CF PharmTech's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-12.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-12.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CF PharmTech's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. CF PharmTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CF PharmTech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -0.21%.

CF PharmTech  (HKSE:02652) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CF PharmTech's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-7.61 * ( 1 - 100% )/( (907.576 + 1116.803)/ 2 )
=-0/1012.1895
=0.00 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1344.227 - 205.385 - ( 371.55 - max(0, 262.229 - 493.495+371.55))
=907.576

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1962.282 - 123.835 - ( 721.644 - max(0, 214.274 - 983.378+721.644))
=1116.803

Note: The Operating Income data used here is one times the annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

CF PharmTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.005/( ( (600.349 + max(-122.351, 0)) + (635.47 + max(61.087, 0)) )/ 2 )
=-12.005/( ( 600.349 + 696.557 )/ 2 )
=-12.005/648.453
=-1.85 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.966 + 50.373 + 38.226) - (205.385 + 0 + 34.531)
=-122.351

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(142.073 + 40.539 + 41.842) - (123.835 + 0 + 39.532)
=61.087

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CF PharmTech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-12.005/5780.896
=-0.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CF PharmTech EBIT Related Terms

CF PharmTech EBIT Historical Data

* Premium members only.

The historical data trend for CF PharmTech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CF PharmTech EBIT Chart

CF PharmTech Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-78.67 24.73 22.39 -12.01

CF PharmTech Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
EBIT -78.67 24.73 22.39 -12.01

HKSE:02652 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CF PharmTech EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CF PharmTech's EV-to-EBIT falls into.


HKSE:02652
15GF Score
CF PharmTech Inc HKSE:02652
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CF PharmTech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-12.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-12.0 Mil mean?
CF PharmTech (HKSE:02652) has a EBIT of HK$-12.0 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CF PharmTech.
Is CF PharmTech's EBIT too high?
CF PharmTech's current EBIT is HK$-12.0 Mil. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's EBIT compare to ZTS?
CF PharmTech's EBIT of HK$-12.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CF PharmTech. CF PharmTech's current EBIT is HK$-12.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current EBIT of HK$-12.0 Mil. The current EBIT is HK$-12.0 Mil. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current EBIT is HK$-12.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CF PharmTech Business Description

Address No. 16, Hucundang Road, Xiangcheng Economic Development District, Jiangsu, Suzhou, CHN
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score

Get the complete analysis for HKSE:02652

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$17.35
Price